(October 26, 2026, Cairo) The launch of the PCV13-TT technology transfer project by Walvax Biotechnology Co., Ltd. (“Walvax”, together with its subsidiaries, the “Group”, stock code: 300142.SZ) and Egypt’s Vaccine and Biotechnology City (VBC), Africa’s largest integrated human vaccine manufacturing facility. was successfully held in Cairo, Egypt, on October 26, 2026, aiming to produce Egypt’s first locally manufactured 13-valent pneumococcal conjugate vaccine (PCV13-TT). The event, attended by Egypt’s Health and Population Minister Khaled Abdel Ghaffar, included the signing of an agreement to begin the technology transfer process.
Upon completion of the project, the locally produced vaccines are expected to be exported to 19 countries across Africa and the Middle East, supporting Egypt as a regional vaccine manufacturing hub.
Pneumococcal disease is one of the leading vaccine-preventable causes of death among children under five worldwide. Professor Xuanyi Wang, Research Scientist, Professor at the Institutes of Biomedical Sciences, Fudan University, and Member of the WHO IVIR-AC, outlined the substantial global and regional burden of pneumococcal disease and the proven impact of PCV immunization.
(Minister Khaled Abdel Ghaffar)
“Introducing the vaccine into the national routine immunization programme before 2030 was a priority to protect children against pneumonia and meningitis. Local production would help reduce costs and ensure a steady supply,” said by Minister Abdel Ghaffar.
By 2027, Egypt aims to strengthen its local vaccine manufacturing capabilities through the Vaccine and Biotechnology City (VBC), with an initial focus on technology transfer and the localization of human vaccine production, positioning Egypt as a leading vaccine manufacturing hub in Africa and the Middle East. Building on this foundation, Egypt plans to expand its manufacturing infrastructure to 16 vaccine production lines, targeting an annual production capacity of 700 million doses by 2030, and to achieve full vaccine self-sufficiency by 2040. The initiative builds on Egypt’s efforts since 2014 to strengthen pharmaceutical and health security. The Minister also highlighted President Abdel-Fattah El-Sisi’s support for the initiative. For Africa, the target is to meet 60 percent of the continent’s vaccine needs through local manufacturing by 2040.
Vaccines & Biotechnology City (VBC), Walvax’s strategic partner in Egypt, is designed to meet European and WHO manufacturing standards. Its first production line covers 6,000 square meters and is expected to produce about 140 million doses annually.
Following the launch, Minister Abdel Ghaffar toured the facility’s production lines with Deputy Health Minister Amr Kandil, WHO Representative in Egypt Naima Abid, and other senior officials.
Dr. Shaozhong Dong, Vice Chairman of Walvax, attended the event and, in his speech, reaffirmed the Company’s commitment to sharing its expertise. He remarked, “Walvax stands ready to be a trusted long-term partner in this journey, working together with our partners to contribute to Egypt's vaccine manufacturing capacity and public health security”.
About 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13-TT)
13-valent Pneumococcal Polysaccharide Conjugate Vaccine is indicated for the prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae for infants and children 6 weeks through 5 years of age. As the 2nd PCV13 in the world, over 37 million doses have been distributed worldwide to date. It has earned full marketing approval from 10+ national regulatory authorities, including PIC/s member states such as Indonesia, Thailand and Jordan, alongside widely recognized regional regulatory bodies from India, Morocco, Egypt, Oman, etc. This product is included in Morocco's and Indonesia's Expanded Programme on Immunization.
About Walvax
Founded in 2001, Walvax Biotechnology Co., Ltd. (Walvax) is a leading vaccine manufacturer, engaged in research and development, manufacturing and distribution of safe and efficacious quality vaccines. Walvax has established 4 advanced technology platforms, based on which, Walvax successfully commercialized 9 licensed vaccines. Walvax's purpose is to help everyone live a healthy life and has delivered vaccine products to 29 countries. For further information please visit https://en.walvax.com/about-us/our-company and follow us on Twitter at @WalvaxBiotech and LinkedIn.